Aquablation therapy shows superior results for prostate treatment

A recent trial has found that Aquablation therapy is as effective as laser enucleation for treating enlarged prostates. The study, called WATER III, was conducted by PROCEPT BioRobotics and included 186 men with prostate sizes between 80 and 180 milliliters. The results were presented at the European Association of Urology Annual Congress in Madrid. After three months, both treatments showed similar improvements in symptoms. However, Aquablation therapy had significantly lower rates of ejaculatory dysfunction and stress incontinence. The study also reported that there were no transfusions needed during Aquablation therapy, highlighting its safety. The CEO of PROCEPT BioRobotics, Reza Zadno, noted that the results support the idea that Aquablation could become the standard care for patients with benign prostatic hyperplasia (BPH). Dr. Naeem Bhojani from the University of Montreal praised the findings, emphasizing the benefits for patients seeking BPH treatment. Both Aquablation therapy and laser enucleation produced similar results, but Aquablation had advantages in preserving sexual function and continence. Aquablation therapy is a robotic-assisted treatment that uses ultrasound to guide the procedure. This allows for more precise targeting of prostate tissue while preserving important anatomy. Overall, the growing clinical evidence suggests that Aquablation therapy may be an effective solution for men suffering from BPH.